Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | TNKS | O95271 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285083 | 1.00 | MAOB (0.80) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL31047782 | 0.99 | MAOB (0.78) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL20876884 | 0.99 | MAOB (0.78) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL6957297 | 0.86 | MAOB (0.71) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL27635896 | 0.85 | MAOB (0.83) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL8117451 | 0.84 | AKR1B1 (0.78) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL22617461 | 0.84 | MAOB (0.76) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL8827849 | 0.84 | AKR1B1 (0.78) | MAOBAKR1B1GAAMAPTKMT2A | |
| SCHEMBL3397825 | 0.83 | MAPT (0.68) | MAOBGAAMAPTKMT2AMEN1 | |
| SCHEMBL29463595 | 0.83 | MAPT (0.68) | MAOBGAAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111201021-B | Chroman monocyclic beta-lactams for the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118496221-A | Chroman monocyclic beta-lactams for the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3691639-B1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11433055-B2 | Chromane monobactam compounds for the treatment of bacterial infections | MERCK SHARP & DOHME LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20200297702-A1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3691639-A1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-111201021-A | Chroman monocyclic β -lactams for use in the treatment of bacterial infections | 默沙东公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3353186-B1 | HIGHLY EFFICIENT NRF2 ACTIVATORS-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION | CENTRE NAT RECH SCIENT (FR) | 2019-08-28 | — | — | EP | disclosed |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20040053992-A1 | Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor | ELI LILLY AND COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| EP-1292589-A2 | METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | MILLENIUM PHARMACEUTICALS, INC. (US) | 2003-03-19 | — | — | EP | disclosed |
| EP-0787723-B1 | CYCLOPROPACHROMENECARBOXYLATE DERIVATIVES | SUNTORY LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| EP-0888327-B1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | MENARINI LAB (ES) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001094335-A2 | METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001092250-A2 | SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-5990142-A | ANTIINFLAMMATORY AGENTS AND ANTIALLERGENS HAVING GOOD ORAL ADSORPTION AND BIOAVAILABILITY; CARDIOTONIC AND ANTIISCHEMIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1999-11-23 | — | — | US | disclosed |
| US-5843988-A | Cyclopropachromencarboxylic acid derivatives | SUNTORY LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0787723-A1 | CYCLOPROPACHROMENECARBOXYLATE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233002-A1 | Synthesis of 2-Acyl substituted chromanes and intermediates thereof | PLA2G7, PAFAH1B2, PAFAH1B3 | MAOB 412/4885AKR1B1 1364/4885GAA 1258/4885 |
| US-11433055-B2 | Chromane monobactam compounds for the treatment of bacterial infections | MGAM, MGAM2, CMBL | MAOB 447/4885AKR1B1 418/4885GAA 370/4885 |
| US-20040053992-A1 | Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor | NOTUM, FAR1, CYP51A1 | MAOB 1458/4885AKR1B1 1075/4885GAA 1430/4885 |
| US-20200297702-A1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, CMBL | MAOB 385/4885AKR1B1 433/4885GAA 355/4885 |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | C1R, RRS1, ARG1 | MAOB 2696/4885AKR1B1 2303/4885GAA 1799/4885 |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | C1R, ARG1, MSR1 | MAOB 2283/4885AKR1B1 2338/4885GAA 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.